Fujirebio Europe will be presenting the LUMIPULSE® G1200 for the first time in Germany at the 10th DGKL congress in Dresden

Product news

Gent, Belgium: October 23 2013 - Fujirebio Europe (previously Innogenetics), a leading international healthcare company that conceives, develops, produces and markets high quality in vitro diagnostics (IVD) testing solutions worldwide, will be presenting its LUMIPULSE® G1200, a fully automated chemiluminescent enzyme immunoassay (CLEIA) system, at the 10th Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL) Congress in the Internationales Congress Center Dresden, Germany, from October 23rd to 26th. The LUMIPULSE® G1200 will be presented at the Fujirebio Europe booth #23 during all 4 days of the congress.

The LUMIPULSE® G1200 was first showcased by Fujirebio Europe in Italy in 2011 and in Spain in 2012 and the system is also available in Asia. Fujirebio has more than 20 years of experience in bringing automated immunoassay testing solutions to the market and the LUMIPULSE® G1200 is just the latest instrument in the LUMIPULSE® series originally introduced in Japan. The quality and performance of the LUMIPULSE® series has today positioned Fujirebio as market leader in Japan in the domain of immunoassay testing of oncology and infectious diseases markers. Today more than 1.300 units of the LUMIPULSE® series perform tests daily in hospitals and clinical laboratories across Japan. 

Apart from its robust and streamlined design the LUMIPULSE® G1200 notably features a unique mono test cartridge concept, a true throughput of 120 tests per hour and a broad assay menu featuring markers for infectious diseases, oncology, thyroid, fertility and bone (non-exhaustive list).

More information about the LUMIPULSE® G1200 can be found at www.fujirebio-europe.com/lumipulse.

This product is not available in the USA and in Canada.

 

About Fujirebio
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics testing solutions. Founded over 60 years ago, the company is recognized as the world-wide leader in oncology for both routine and novel markers and has a strong reputation in Japan within infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been successfully marketing automated immunoassay testing solutions and has, under the name Innogenetics (now Fujirebio Europe), pioneered the field of molecular diagnostics and multiparameter testing. It is today among the world-leaders in strip-based diagnostics solutions.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.